The pharmaceutical industry reflected on its performance in 2024, with several key takeaways. The US Food and Drug Administration approved numerous long-awaited new treatments, including first-in-class medicines. However, the high prices of these new drugs raised concerns about unequal access to healthcare, particularly for low- and middle-income countries.
Despite economic headwinds, investors remained cautious and focused on established names and business areas. Nevertheless, the industry demonstrated resilience, continuing to develop innovative solutions to address patients’ needs.
This year’s regulatory landscape saw several notable developments, including new authorizations and the impact of changing administrations on the industry. The rise of authorized versions and illegal copies of GLP-1 agonists highlighted the ongoing challenges in ensuring access to affordable medicines.
As the pharmaceutical industry looks ahead to 2025, it must address these pressing issues. While progress has been made, more needs to be done to ensure equal access to life-saving treatments for all patients, regardless of their income level or geographic location.
Source: https://cen.acs.org/pharmaceuticals/CENs-Year-Pharma-2024/102/i38